Cytodyn Inc 's Cash & cash equivalent grew by 38.03 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Cytodyn Inc 's Quick Ratio to 0.33, Quick Ratio remained below Cytodyn inc average.

Within Major Pharmaceutical Preparations industry 403 other companies have achieved higher Quick Ratio than Cytodyn Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 3095, from total ranking in the fourth quarter 2026 at 4984.

Explain Quick Ratio?
How much Cash & cash equivalents CYDY�s has?
What are CYDY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CYDY Quick Ratio	(Aug 31 2026) Q1	(May 31 2026) Q4	(Feb 28 2026) Q3	(Nov 30 2025) Q2	(Aug 31 2025) Q1
Y / Y Current Liabilities Change	-28.4 %	-23.81 %	-28.54 %	20.51 %	-0.2 %
Y / Y Cash & cash equivalent Change	75.3 %	-0.43 %	-4.54 %	-87.68 %	-62.55 %
Quick Ratio MRQ	0.33	0.22	0.31	0.06	0.13
CYDY's Total Ranking	# 3095	# 4984	# 4332	# 4230	# 3953
Seq. Current Liabilities Change	-7.5 %	6.54 %	-40.75 %	22.61 %	-1.56 %
Seq. Cash & cash equivalent Change	38.03 %	-24.29 %	214.23 %	-46.61 %	-21.6 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 404
Healthcare Sector	# 775
Overall Market	# 2995

Quick Ratio Statistics
High	Average	Low
4.27	0.53	0
(Feb 29 2016)		(Nov 30 2023)

Financial Statements
Cytodyn Inc 's Current Liabilities	$ 50 Millions	Visit CYDY's Balance sheet
Cytodyn Inc 's Cash & cash equivalent	$ 16 Millions	Visit CYDY's Balance sheet
Source of CYDY's Sales		Visit CYDY's Sales by Geography

Cumulative Cytodyn Inc 's Quick Ratio

CYDY's Quick Ratio for the trailling 12 Months

CYDY Quick Ratio	(Aug 31 2026) 12 Months	(May 31 2026) 12 Months	(Feb 28 2026) 12 Months	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-15 %	-8.03 %	-6.6 %	-16.46 %	-30.86 %
Y / Y Cash & cash equivalent TTM Growth	-37.43 %	-55.35 %	-50.66 %	-39.01 %	163.91 %
Quick Ratio TTM	0.2	0.16	0.15	0.14	0.28
Total Ranking TTM	# 2904	# 3437	# 2772	# 2615	# 2815
Seq. Current Liabilities TTM Growth	-7.62 %	-6.1 %	-6.81 %	5.15 %	-0.05 %
Seq. Cash & cash equivalent TTM Growth	16.8 %	-0.12 %	-1.75 %	-45.41 %	-16.64 %

Quick ratio ranking by company, industry and sector >> Back to CYDY Financial Strength Comparisons >> Go to Compare CYDY Quick Ratio to its Competitors

On the trailing twelve months basis CYDY Cash & cash equivalent soared by 75.3 % in Q1 2026 year on year, while Current Liabilities decreased to $50 millions, this led to increase in in Cytodyn Inc 's Quick Ratio to 0.2, Quick Ratio remained below CYDY average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Cytodyn Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending fourth quarter 2026 at 4091.

Explain Quick Ratio?
How much Cash & cash equivalents CYDY�s has?
What are CYDY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 909
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.5	0.39	0.02
(Nov 30 2016)

Companies with similar Quick Ratio in the quarter ending Aug 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Aug 31 2026 MRQ Cash & cash equivalent	Aug 31 2026 MRQ Current Liabilities
Mirum Pharmaceuticals Inc	0.86	$ 243.188 Millions	$ 283.080 Millions
Amphastar Pharmaceuticals Inc	0.86	$ 262.786 Millions	$ 306.303 Millions
Aclaris Therapeutics Inc	0.84	$ 20.394 Millions	$ 24.222 Millions
Seres Therapeutics Inc	0.84	$ 17.528 Millions	$ 20.893 Millions
Jazz Pharmaceuticals Plc	0.80	$ 2,036.400 Millions	$ 2,540.300 Millions
Zomedica Corp	0.80	$ 7.281 Millions	$ 9.096 Millions
Pfizer Inc	0.79	$ 25,140.000 Millions	$ 31,726.000 Millions
Xencor Inc	0.78	$ 59.622 Millions	$ 76.266 Millions
Janux Therapeutics Inc	0.77	$ 41.818 Millions	$ 54.247 Millions
Arcus Biosciences Inc	0.76	$ 151.000 Millions	$ 199.000 Millions
Ligand Pharmaceuticals Incorporated	0.75	$ 374.303 Millions	$ 500.569 Millions
Bristol myers Squibb Company	0.67	$ 12,581.000 Millions	$ 18,753.000 Millions
Supernus Pharmaceuticals inc	0.62	$ 176.171 Millions	$ 285.397 Millions
Axsome Therapeutics Inc	0.62	$ 313.859 Millions	$ 509.719 Millions
Travere Therapeutics Inc	0.59	$ 123.542 Millions	$ 210.912 Millions
Clene Inc	0.58	$ 9.887 Millions	$ 17.114 Millions
Zoetis Inc	0.57	$ 1,533.000 Millions	$ 2,682.000 Millions
Organon and Co	0.55	$ 1,455.000 Millions	$ 2,652.000 Millions
Medicus Pharma Ltd	0.52	$ 5.020 Millions	$ 9.743 Millions
Bausch Health Companies Inc	0.51	$ 2,485.000 Millions	$ 4,895.000 Millions
Neonc Technologies Holdings Inc	0.49	$ 10.966 Millions	$ 22.241 Millions
Royalty Pharma Plc	0.46	$ 544.857 Millions	$ 1,179.003 Millions
Organogenesis Holdings Inc	0.45	$ 21.326 Millions	$ 47.649 Millions
Inmed Pharmaceuticals Inc	0.43	$ 1.140 Millions	$ 2.673 Millions
Kiniksa Pharmaceuticals International Plc	0.43	$ 81.660 Millions	$ 191.855 Millions
Syndax Pharmaceuticals Inc	0.40	$ 146.094 Millions	$ 361.833 Millions
Vanda Pharmaceuticals Inc	0.40	$ 62.038 Millions	$ 154.980 Millions
Ultragenyx Pharmaceutical Inc	0.39	$ 150.000 Millions	$ 389.000 Millions
Biomarin Pharmaceutical Inc	0.38	$ 736.007 Millions	$ 1,913.942 Millions
Aurinia Pharmaceuticals Inc	0.36	$ 45.792 Millions	$ 127.629 Millions

Date modified: 2026-10-15T04:50:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.